Cognition Therapeutics Inc (CGTX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.64-7.01%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · CGTX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
We are focused on initiating our Phase 3 study in mid-2027 with an improved tablet composition.
Stated in 2 of 2 supplied quarters. Management reported: “We are focused on initiating our Phase 3 study in mid-2027 with an improved tablet composition.” “The registrational program is expected to begin in mid-2027.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“We are focused on initiating our Phase 3 study in mid-2027 with an improved tablet composition.”
““We filed a request to meet with the Food and Drug Administration’s Division of Psychiatry to discuss our plans for a registrational study in people with dementia with Lewy body (DLB) psychosis,” sta…”
The decrease in research and development expenses was driven by lower trial activities with contract research organizations, compensation and professional fees.
Stated in 2 of 2 supplied quarters. Management reported: “Research and development expenses were $5.1 million for the quarter ended June 30, 2026, compared to $11.5 million for the comparable period in 2025.” “Research and development expenses were $6.1 million for the quarter ended March 31, 2026, compared to $10.8 million for the comparable period in 2025.”
“The decrease in research and development expenses was driven by lower trial activities with contract research organizations, compensation and professional fees.”
“The decrease in research and development expenses was driven by lower trial activities with contract research organizations and professional fees.”
The Company estimates that it has sufficient cash to fund operations and capital expenditures into the fourth quarter of 2027.
Stated in 2 of 2 supplied quarters. Management reported: “The Company estimates that it has sufficient cash to fund operations and capital expenditures into the fourth quarter of 2027.” “The Company estimates that it has sufficient cash to fund operations and capital expenditures through the second quarter of 2027.”
“The Company estimates that it has sufficient cash to fund operations and capital expenditures into the fourth quarter of 2027.”
“The Company estimates that it has sufficient cash to fund operations and capital expenditures through the second quarter of 2027.”
About Zervimesine (CT1812) Zervimesine (CT1812) is currently being studied in the Phase 2 START Study ( NCT05531656 ) in patients with MCI and early Alzheimer’s disease.
Stated in 2 of 2 supplied quarters. Management reported: “Topline results from the 545-participant Phase 2 ‘START’ COG0203 (NCT05531656) study in mild cognitive impairment (MCI) and early Alzheimer's disease are anticipated in 2027.” “About Zervimesine (CT1812) Zervimesine (CT1812) is currently being studied in the Phase 2 START Study ( NCT05531656 ) in patients with MCI and early Alzheimer’s disease.”
“About Zervimesine (CT1812) Zervimesine (CT1812) is currently being studied in the Phase 2 START Study ( NCT05531656 ) in patients with MCI and early Alzheimer’s disease.”
“Topline results from the 545-participant Phase 2 ‘START’ COG0203 (NCT05531656) study in mild cognitive impairment (MCI) and early Alzheimer's disease are anticipated in 2027.”
Advance clinical development of zervimesine in Alzheimer's disease through the ongoing Phase 2 START study with topline results expected in 2027.
Over the trailing year it converted 0.93x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
3 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-04.